| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Cancer Research, Vol 2, Issue 5 821-826, Copyright © 1996 by American Association for Cancer Research
ARTICLES |
Y Yamamoto, M Toi, S Kondo, T Matsumoto, H Suzuki, M Kitamura, K Tsuruta, T Taniguchi, A Okamoto, T Mori, M Yoshida, T Ikeda and T Tominaga
Department of Surgery, Tokyo Metropolitan Komagome Hospital, 3-18-22, Honkomagome, Bunkyo-ku, Tokyo, 113, Japan.
Vascular endothelial growth factor (VEGF) is known to play crucial roles in tumor angiogenesis. We have investigated the circulating level of VEGF in sera from cancer patients as well as from healthy normal controls using a sensitive enzymatic immunoassay. Immunoreactive VEGF proteins were detectable in normal sera, and the cutoff level was determined to be 180 pg/ml. In examined patients with all types of cancer, including breast, gastrointestinal, hepatobiliary, and lung cancer, an aberrant increase in the circulating level of VEGF was detected. For example, in 137 primary breast cancer patients, 12 (8.8%) showed an aberrant increase in VEGF levels. This aberrant expression of VEGF in sera was significantly associated with the progression of the disease, and with VEGF protein expression in tumor tissues. In addition, a Western blot analysis confirmed the presence of the VEGF165 form in sera from a patient with recurrent breast cancer. It was concluded that VEGF was detectable in normal sera, and its level was increased in some populations of cancer patients. A positive angiogenesis regulator, VEGF might function as an endocrine growth factor, particularly for solid tumors.
This article has been cited by other articles:
|
|
 |
|
  C. E. Holmes, J. C. Huang, T. R. Pace, A. B. Howard, and H. B. Muss Tamoxifen and Aromatase Inhibitors Differentially Affect Vascular Endothelial Growth Factor and Endostatin Levels in Women with Breast Cancer Clin. Cancer Res., May 15, 2008; 14(10): 3070 - 3076. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Caballero, J. J. Grau, J. L. Blanch, J. Domingo-Domenech, J. M. Auge, W. Jimenez, and M. Bernal-Sprekelsen Serum Vascular Endothelial Growth Factor as a Predictive Factor in Metronomic (Weekly) Paclitaxel Treatment for Advanced Head and Neck Cancer Arch Otolaryngol Head Neck Surg, November 1, 2007; 133(11): 1143 - 1148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. I. Rini and W.K. Rathmell Biological Aspects and Binding Strategies of Vascular Endothelial Growth Factor in Renal Cell Carcinoma Clin. Cancer Res., January 15, 2007; 13(2): 741s - 746s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S M Hyder Sex-steroid regulation of vascular endothelial growth factor in breast cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 667 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zhou, R.-R. Zhou, H. Guan, C. D. Bucana, and E. S. Kleinerman E1A gene therapy inhibits angiogenesis in a Ewing's sarcoma animal model Mol. Cancer Ther., December 1, 2003; 2(12): 1313 - 1319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Santini, B. Vincenzi, G. Dicuonzo, G. Avvisati, C. Massacesi, F. Battistoni, M. Gavasci, L. Rocci, M. C. Tirindelli, V. Altomare, et al. Zoledronic Acid Induces Significant and Long-Lasting Modifications of Circulating Angiogenic Factors in Cancer Patients Clin. Cancer Res., August 1, 2003; 9(8): 2893 - 2897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Heer Reply Clin. Cancer Res., August 1, 2003; 9(9): 3515 - 3515. [Full Text] [PDF]
|
|
|
|
 |
|
 R. T.-P. Poon, C. P.-Y. Lau, S.-T. Cheung, W.-C. Yu, and S.-T. Fan Quantitative Correlation of Serum Levels and Tumor Expression of Vascular Endothelial Growth Factor in Patients with Hepatocellular Carcinoma Cancer Res., June 15, 2003; 63(12): 3121 - 3126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Laack, A. Kohler, C. Kugler, T. Dierlamm, C. Knuffmann, G. Vohwinkel, A. Niestroy, N. Dahlmann, A. Peters, J. Berger, et al. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer Ann. Onc., October 1, 2002; 13(10): 1550 - 1557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Robak, A Wozaniacka, A Sysa-Jedrzejowska, H Stepien, and T Robak Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus Lupus, June 1, 2002; 11(6): 348 - 355. [Abstract] [PDF]
|
|
|
|
|
|
D. Santini, B. Vincenzi, G. Avvisati, G. Dicuonzo, F. Battistoni, M. Gavasci, A. Salerno, V. Denaro, and G. Tonini Pamidronate Induces Modifications of Circulating Angiogenetic Factors in Cancer Patients Clin. Cancer Res., May 1, 2002; 8(5): 1080 - 1084. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Heer, H. Kumar, J. R. Read, J. N. Fox, J. R. T. Monson, and M. J. Kerin Serum Vascular Endothelial Growth Factor in Breast Cancer: Its Relation with Cancer Type and Estrogen Receptor Status Clin. Cancer Res., November 1, 2001; 7(11): 3491 - 3494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Sezer, C. Jakob, K. Niemoller, R. T.P. Poon, S.-T. Fan, and J. Wong Angiogenesis in Cancer J. Clin. Oncol., July 1, 2001; 19(13): 3299 - 3301. [Full Text]
|
|
|
|
|
|
J. A. Foekens, H. A. Peters, N. Grebenchtchikov, M. P. Look, M. E. Meijer-van Gelder, A. Geurts-Moespot, T. H. van der Kwast, C. G. J. Sweep, and J. G. M. Klijn High Tumor Levels of Vascular Endothelial Growth Factor Predict Poor Response to Systemic Therapy in Advanced Breast Cancer Cancer Res., July 1, 2001; 61(14): 5407 - 5414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. C. Levitt, F. A. L. M. Eskens, K. J. O'Byrne, D. J. Propper, L. J. Denis, S. J. Owen, L. Choi, J. A. Foekens, S. Wilner, J. M. Wood, et al. Phase I and Pharmacological Study of the Oral Matrix Metalloproteinase Inhibitor, MMI270 (CGS27023A), in Patients with Advanced Solid Cancer Clin. Cancer Res., July 1, 2001; 7(7): 1912 - 1922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. George, S. Halabi, T. F. Shepard, N. J. Vogelzang, D. F. Hayes, E. J. Small, and P. W. Kantoff Prognostic Significance of Plasma Vascular Endothelial Growth Factor Levels in Patients with Hormone-refractory Prostate Cancer Treated on Cancer and Leukemia Group B 9480 Clin. Cancer Res., July 1, 2001; 7(7): 1932 - 1936. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-D. Tabone, J. Landman-Parker, B. Arcil, M.-C. Coudert, I. Gerota, M. Benbunan, G. Leverger, and C. Dosquet Are Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor Prognostic Indicators in Pediatric Patientswith Malignant Solid Tumors? Clin. Cancer Res., March 1, 2001; 7(3): 538 - 543. [Abstract] [Full Text]
|
|
|
|
|
|
R. T.-P. Poon, S.-T. Fan, and J. Wong Clinical Implications of Circulating Angiogenic Factors in Cancer Patients J. Clin. Oncol., February 15, 2001; 19(4): 1207 - 1225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ugurel, G. Rappl, W. Tilgen, and U. Reinhold Increased Serum Concentration of Angiogenic Factors in Malignant Melanoma Patients Correlates With Tumor Progression and Survival J. Clin. Oncol., January 15, 2001; 19(2): 577 - 583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Slevin, J. Krupinski, A. Slowik, P. Kumar, A. Szczudlik, and J. Gaffney Serial Measurement of Vascular Endothelial Growth Factor and Transforming Growth Factor-{beta}1 in Serum of Patients With Acute Ischemic Stroke Stroke, August 1, 2000; 31(8): 1863 - 1870. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Adams, P. J. Carder, S. Downey, M. A. Forbes, K. MacLennan, V. Allgar, S. Kaufman, S. Hallam, R. Bicknell, J. J. Walker, et al. Vascular Endothelial Growth Factor (VEGF) in Breast Cancer: Comparison of Plasma, Serum, and Tissue VEGF and Microvessel Density and Effects of Tamoxifen Cancer Res., June 1, 2000; 60(11): 2898 - 2905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Hyder, Z. Nawaz, C. Chiappetta, and G. M. Stancel Identification of Functional Estrogen Response Elements in the Gene Coding for the Potent Angiogenic Factor Vascular Endothelial Growth Factor Cancer Res., June 1, 2000; 60(12): 3183 - 3190. [Abstract] [Full Text]
|
|
|
|
|
|
S. Ramanujan, G. C. Koenig, T. P. Padera, B. R. Stoll, and R. K. Jain Local Imbalance of Proangiogenic and Antiangiogenic Factors: A Potential Mechanism of Focal Necrosis and Dormancy in Tumors Cancer Res., March 1, 2000; 60(5): 1442 - 1448. [Abstract] [Full Text]
|
|
|
|
|
|
P. Salven, A. Orpana, and H. Joensuu Leukocytes and Platelets of Patients with Cancer Contain High Levels of Vascular Endothelial Growth Factor Clin. Cancer Res., March 1, 1999; 5(3): 487 - 491. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. S. Lin, C. Nguyen, J.-L. Mendoza, E. Escandon, D. Fei, Y. G. Meng, and N. B. Modi Preclinical Pharmacokinetics, Interspecies Scaling, and Tissue Distribution of a Humanized Monoclonal Antibody against Vascular Endothelial Growth Factor J. Pharmacol. Exp. Ther., January 1, 1999; 288(1): 371 - 378. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. Salven, L. Teerenhovi, and H. Joensuu A High Pretreatment Serum Vascular Endothelial Growth Factor Concentration Is Associated With Poor Outcome in Non-Hodgkin's Lymphoma Blood, October 15, 1997; 90(8): 3167 - 3172. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
